->

AstraZeneca yakanangwa nemishonga Acalabrutinib ine nzira nyowani yekurapa isingagumi lymphocytic leukemia

Share This Post

Acalabrutinib ndeyechipiri-chizvarwa tyrosine kinase (BTK) inhibitor, mushonga mutsva unogona kuvandudza kupona kwechirwere chechirwere che lymphocytic leukemia (CLL) uye mantle cell lymphoma (MCL).

Vatsvagiri vanotenda kuti BTK inhibitors yakasanganiswa neyakagadziridzwa CD20 antibody mishonga (yakadai seObinutuzumab) inogona kuvandudza kukurumidza uye kudzika kwekurapa kweAcalabrutinib nekupindura mamwe maseru egomarara.

MuChikamu 1 b / II kiriniki yekuyedza, ivo vaongorori vakaongorora mabatiro ehurongwa hwakabatana hweAcalabrutinib naObinutuzumab kuOhio State University Comprehensive Cancer Center-James Cancer Hospital-Richard Research Center (OSUCCC-James), kuunganidza makumi mana makumi mana kana varwere veCLL vasina kumbowana kurapwa.

Pakazara, iyo yekubatanidza kurapa kweAcalabrutinib uye Obinutuzumab inoregererwa zvakanaka, uye mwero wekupindura wakavandudza nekufamba kwenguva.

Pakati pevarwere vanga vasati vagamuchira chero kurapwa, huwandu hwekupindura huwandu hwaive 95%. Iyo yepakati yekutevera nguva yaive 17.8 mwedzi. Iyo yakazara yekupona rate (OS) yevarwere vakadzokerazve / yekutsoropodza CLL yaive 92%, iine yepakati yekutevera nguva yemwedzi makumi maviri neimwe.

OSUCCC-James. Sangana naPurofesa uye wekutanga munyori Jennifer Woyach vakati kunyangwe kufambira mberi kwakaitwa pakurapa kweCLL mumakore apfuura, kudiwa kwekuwedzera mamwe marapirwo kuchiri kukurumidza.

Kubudirira kwese kweyeyedzo yeAcalabrutinib kunosimbisa kuti chidzidzo chekiriniki ichi chinogona kuve nekukanganisa manejimendi eCLL.

Subscribe To Newsletter Vedu

Wana zvigadziriso uye usambopotsa blog kubva kuCancerfax

Zvimwe Kuti Uongorore

Kurapa Kwemasero eCAR T kunoitwa nevanhu: Kubudirira Uye Zvinetso
CAR T-Cell kurapa

Kurapa Kwemasero eCAR T: Kubudirira uye Zvinetso

Human-based CAR T-cell therapy inosandura kurapwa kwegomarara nekugadzirisa magene masero emuviri emurwere kuti anange nekuparadza maseru egomarara. Nekushandisa simba rekudzivirira kwemuviri, marapirwo aya anopa marapiro ane simba uye emunhu ane mukana wekuregererwa kwenguva refu mumhando dzakasiyana dzegomarara.

arun Dai 4, 2024
Kunzwisisa Cytokine Release Syndrome: Zvinokonzera, Zviratidzo, uye Kurapa
CAR T-Cell kurapa

Kunzwisisa Cytokine Release Syndrome: Zvinokonzera, Zviratidzo, uye Kurapa

Cytokine Release Syndrome (CRS) is immune system reaction inowanzo kukonzerwa nemamwe marapirwo senge immunotherapy kana CAR-T cell therapy. Zvinosanganisira kuburitswa kwakanyanya kwemacytokines, zvichikonzera zviratidzo kubva pafivha uye kuneta kusvika kune zvinogona kuuraya hupenyu sekukuvadzwa kwenhengo. Kutungamira kunoda kunyatsotarisisa uye nzira dzekupindira.

Alysha Mendossa April 29, 2024

Kuda rubatsiro? Chikwata chedu chakagadzirira kukubatsira.

Tinoshuvira kupora nekukurumidza kwemudiwa wako uye padyo neuyo.

Taura nesu
Kutanga kutaura
Tiri paIndaneti! Taura Nesu!
Skena kodhi
Mhoro,

Kugamuchirwa kuCancerFax!

CancerFax ipuratifomu yekupayona yakatsaurirwa kubatanidza vanhu vakatarisana negomarara repamberi nekurapa kwesero seCAR T-Cell therapy, TIL kurapwa, uye miedzo yekiriniki pasi rese.

Tizivise zvatinogona kukuitira.

1) Kurapwa kwegomarara kunze kwenyika?
2) CAR T-Cell therapy
3) Mushonga wegomarara
4) Online vhidhiyo kubvunza
5) Proton kurapwa